Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2021-01-11 Regulatory Filings
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 11, 2021, announcing that THERADIAG has obtained CE marking for four new i-Tracker® test kits and declared their market launch to the ANSM (French National Agency for the Safety of Medicines and Health Products). This is a specific operational/product update, not a comprehensive financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is an announcement of a significant business event (product approval/launch). While it mentions future financial events (Annual Revenue, Annual Results, AGM), the primary content is the CE marking announcement. This type of specific, non-financial regulatory/operational announcement that doesn't fit other specific categories (like DIRS, MANG, TAR) is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it were about fundraising, but here it is about product regulatory clearance. Given the options, RNS serves as the best general regulatory announcement fallback for specific operational news that isn't a core financial filing or management change. The document length (4911 chars) is substantial enough that it is the announcement itself, not just a brief notice of publication (RPA).
2021-01-11 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated January 11, 2021, announcing that THERADIAG obtained CE marking for four new i-Tracker® test kits. It details product development, regulatory registration (ANSM), and includes a financial calendar mentioning the upcoming FY 2020 revenue, FY 2020 results, and the Annual General Meeting (AGM) date (May 6, 2021). Since the core content is a product/regulatory update (CE marking) and not a formal financial report (like 10-K or IR) or a specific announcement about management changes, dividends, or share transactions, it best fits the general Regulatory Filings category (RNS) as a miscellaneous regulatory/operational announcement, or potentially a general Investor Relations document. Given the specific nature of the announcement (product regulatory approval), RNS is the most appropriate fallback for non-standard filings. It is not an ER, IR, or MDA as it focuses on product news, not financial performance summary. It is not an AGM-R or DEF 14A as it precedes those events.
2021-01-11 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité Theradiag avec Portzamparc" (Semi-annual balance sheet of the Theradiag liquidity contract with Portzamparc) and reports the status of the liquidity contract as of December 31, 2020. It details the number of shares and cash held under the contract, as well as the total purchases and sales executed during the second half of 2020. This type of regular disclosure regarding market making or liquidity agreements is a specific regulatory or contractual requirement, but it does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a specific type of corporate action/disclosure related to market stability and shareholder interest. Since it is a specific, periodic report detailing financial/market activity that isn't a standard earnings release or quarterly report, and it is not a general announcement of a report being published (RPA), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is a required disclosure to the market regarding a specific agreement. *Self-Correction/Refinement*: While it details financial activity, it is not an Earnings Release (ER) or Interim Report (IR). It is a report on a specific agreement (liquidity contract). Given the options, RNS (Regulatory Filings) is the best fit for specific, non-standard periodic disclosures.
2021-01-07 French
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is titled "THERADIAG announces its 2021 financial calendar" and explicitly lists the dates for future financial events, including the release of 2020 Full-Year Results, the Annual General Meeting (AGM), and First-Half Results. This document is an announcement about the schedule of future corporate events and report publications, rather than the reports themselves. Given the short length (2609 chars) and the nature of announcing when reports will be published, it fits the definition of a Report Publication Announcement (RPA). It is not a specific regulatory filing like 10-K or ER, but rather a notice about when those filings/events will occur.
2020-12-15 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "THERADIAG annonce son agenda financier 2021" (THERADIAG announces its 2021 financial calendar). It explicitly lists future dates for key financial events such as annual revenue, annual results, the Annual General Meeting (AGM), and interim results. This document is not the actual financial report (like 10-K or IR) but an announcement detailing *when* those reports and events will occur. According to the definitions, an announcement regarding the timing or publication of company reports falls under 'Report Publication Announcement' (RPA). The document is short and serves to inform stakeholders about future releases.
2020-12-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is a press release dated December 14, 2020, announcing the publication of a clinical study that validates the quality of Theradiag's antigenic tests according to French National Authority for Health (HAS) requirements. It details the study's methodology and results, and includes boilerplate information about the company and investor relations contacts. This type of announcement, which reports on a specific event or finding (a study validation) rather than routine financial performance (ER, IR, 10-K) or management changes (MANG), fits best under the general 'Regulatory Filings' (RNS) category, as it pertains to compliance and regulatory acceptance of a product, or potentially 'LTR' if viewed as a regulatory compliance update, but RNS is the broader category for miscellaneous regulatory announcements not covered elsewhere. Given the focus on regulatory compliance validation for a medical test, RNS is the most appropriate general classification for this type of corporate news release that isn't a standard financial report or insider transaction.
2020-12-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.